ARS Pharmaceuticals Sees Chairman and Chief Medical Officer Depart on Same Day
SPRY is trading near its 52-week low of $6.66 (5.6% above the low).
Summary
ARS Pharmaceuticals disclosed the same-day departure of Chairman Richard Lowenthal and Chief Medical Officer Sarina Tanimoto, with severance payments totaling $329,130. The exits follow a recent product setback and CEO change, signaling deepening leadership turmoil.
Key Events · Executive and Board Changes · SPRY
-
Chairman Resigns as Part of Severance
Effective July 15, 2026, Richard Lowenthal resigned from the Board—a move required by his severance agreement. He will receive a one-time payment of $217,350, which represents his prorated 2026 target bonus.
-
Chief Medical Officer Terminated Without Cause
Sarina Tanimoto, M.D., was terminated as Chief Medical Officer on July 15, 2026. Her severance includes a one-time payment of $111,780, equal to her prorated 2026 target bonus.
-
Leadership Vacuum Amid Commercial Challenges
The departures follow a June 2026 failure of Neffy to secure new commercial coverage, which caused a 23% stock drop, and a July 2026 CEO transition to Donn Casale. The company now lacks a Chairman and CMO during a critical period.
-
Severance Costs Total $329,130
Combined one-time payments to Lowenthal and Tanimoto amount to $329,130, in addition to standard severance benefits described in the proxy statement.
Analysis · SPRY · Life Sciences
On July 15, 2026, the company lost two senior leaders: Richard Lowenthal resigned from the Board as a condition of his severance package, and Chief Medical Officer Sarina Tanimoto was terminated without cause. The one-time severance payments amount to $217,350 for Lowenthal and $111,780 for Tanimoto, each representing their prorated 2026 target bonuses. These exits arrive just weeks after Neffy, the company's key product, failed to secure new commercial coverage—a setback that triggered a 23% stock plunge—and amid a recent CEO transition to Donn Casale. The simultaneous loss of a board member and the top medical officer during a period of commercial and leadership upheaval raises concerns about strategic stability.
At the time of this filing, SPRY was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695.1M. The 52-week trading range was $6.66 to $18.63. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.